People Who Live Past 110 Have Unusual Killer T Cells. Scientists Think They Know Why.

If you have ever wondered what separates the handful of humans who make it past 110 from everyone else, a new study points to a surprising possibility: a rare class of immune cells that quietly expands late in life and may spend its time hunting down tumors, zombie cells, and reactivated viruses. The research, published in Cell Reports, is early and in a small cohort, but what it found in the blood of supercentenarians is striking enough to reframe how immunologists think about aging.

Key takeaways:

• A T cell type called CD4 CTL reaches a median of 17.6% of CD4 T cells in supercentenarians, far above levels seen in people in their 70s and 80s.
• These cells are clonally expanded (meaning a few dominant clones dominate) and show no signs of exhaustion, which is unusual for heavily differentiated immune cells.
• Their receptor sequences overlap with those found in cancer patients, hinting at possible tumor surveillance roles.
• This is early, investigational research on a small cohort; none of this translates to a clinical intervention yet.

CD4 Killer T Cells Reach 17.6% in Supercentenarians

The cells at the center of this study are called CD4 CTLs, short for CD4-positive cytotoxic T lymphocytes. Most people know T cells come in two main flavors: CD4 "helper" cells that coordinate immune responses, and CD8 "killer" cells that directly destroy infected or cancerous targets. CD4 CTLs blur that line. They carry the CD4 marker of a helper cell but also pack cytotoxic machinery, specifically granzyme B and perforin, the molecular weapons CD8 killers use to punch holes in target cells.

These hybrid cells have been spotted in various disease contexts before, but their role in healthy aging had been murky. To clarify it, researchers analyzed T cells from eight donors in their 70s to 90s, ten centenarians (around 100 years old), and ten supercentenarians (110 or older) using single-cell immune profiling that simultaneously captured each cell's gene activity, surface proteins, and T cell receptor sequences. They also built a machine-learning model, a multi-task variational autoencoder, to integrate data from 1,512 samples spanning ages 0 to 110-plus from public datasets, giving them a population-level view of how CD4 CTLs shift over a lifetime.

The pattern was unambiguous. CD4 CTLs climbed steadily with age and then accelerated sharply around the century mark, reaching a median of 17.6% of all CD4 T cells in supercentenarians. By contrast, these cells are rare in middle-aged adults. The top clones within this population were enormous: on average, a single clone occupied 33.3% of the CD4 CTL compartment, meaning the immune system had made massive bets on a small number of receptor specificities.

Why People With Autoimmune Conditions or Cancer Risk Should Pay Attention

For readers tracking their own immune health, the conceptual stakes here are significant, even if the clinical translation is still far off. CD4 CTLs sit at an intersection that matters for several conditions people commonly research: cancer immunosurveillance, senescent cell clearance (relevant to inflammatory and autoimmune conditions), and the control of reactivated viruses like cytomegalovirus (CMV), which most adults carry silently and which is known to drive immune aging.

The study authors hypothesize that the expansion of CD4 CTLs represents an adaptive response to antigens, the molecular flags that trigger immune recognition, displayed on MHC class II molecules (the surface proteins that normally activate helper T cells rather than killers). Persistent MHC class II-displaying targets that accumulate late in life could include senescent cells (dysfunctional aging cells that secrete inflammatory signals), tumor cells, and cells reactivated by latent viruses. Prior work has shown CD4 CTLs can eliminate senescent cells by targeting CMV antigens, suggesting the immune system may have a dedicated late-life clean-up mechanism that some people deploy more effectively than others.

The authors also flag a potential downside. The same cells that clear damaged tissue could, in different contexts, cause pathological damage to healthy tissue. They describe CD4 CTLs as a possible "double-edged sword," and that framing is worth keeping in mind: robust immune surveillance is not unconditionally good.

How the Team Mapped CD4 CTL Differentiation

One of the more technically impressive parts of the study was tracing how these cells develop. The researchers used the pattern of surface protein loss as a timeline. CD4 CTLs in supercentenarians predominantly show a CD27-negative, CD28-negative profile: two co-stimulatory proteins that helper T cells normally carry get stripped away as the cells mature. But the researchers also identified a CD27-negative, CD28-positive intermediate population, a transitional state that suggests a defined sequential pathway from conventional helper cell to cytotoxic killer.

Importantly, these cells did not look exhausted. Exhaustion, marked by PD-1 expression and collapsed effector function, is what typically happens when T cells face chronic antigen stimulation. Here, the CD4 CTLs were PD-1 negative despite being heavily differentiated, suggesting they remain functional. They also expressed GPR56 (also called ADGRG1), a surface marker previously identified in lung cancer CTLs, reinforcing the tumor-surveillance hypothesis.

The T cell receptor (TCR) sequences added another layer. The researchers searched public TCR databases using the receptor sequences from the largest CD4 CTL clones and found that CDR3 beta sequences, the part of the receptor that makes direct contact with antigens, from healthy supercentenarians with no known cancer history matched sequences found expanded in cancer patients, particularly in non-small cell lung cancer (NSCLC). The standardization challenges inherent in translating single-cell immune data into clinical conclusions mean these matches are exploratory, not diagnostic. But they raise the possibility that supercentenarians are mounting immune responses to subclinical tumor activity that never progresses to clinical disease.

What This Could Mean for Someone Watching Their Immune Health

For now, this research does not translate into anything you can do or take. No supplement, diet, or intervention is established to expand CD4 CTLs, and this study does not claim otherwise. What it does is point toward a potentially measurable immune signature of resilience: people who reach extreme old age in good health appear to have mounted a specialized, non-exhausted cytotoxic response using a cell type most immunologists had not been closely watching.

If you are managing an autoimmune condition, an inflammatory disease, or simply tracking your immune age, CD4 CTLs are not yet part of any standard clinical panel. But the finding that these cells show distinct interleukin profiles, including subgroups with Th2-like (IL-4, IL-13) and Tfh-like (IL-21) cytokine patterns, within the same clone suggests a plasticity that could eventually be leveraged therapeutically. The broader relationship between immune cell programming and metabolic disease risk adds further context: the immune system's behavior in aging is not isolated from the metabolic environment it operates in.

Limitations: Small Cohort, No In-Vivo Validation

The study's weaknesses are real and acknowledged by the authors. The centenarian and supercentenarian cohort was small, just ten individuals in each group, which means individual variation could be hiding important patterns. The TCR database matches relied only on CDR3 beta sequences, not the full receptor, so confirmed antigen targets remain unknown. All functional data came from cells stimulated outside the body using PMA and ionomycin, which is a standard but artificial activation method that may not perfectly replicate what happens in living tissue. And there is no direct evidence yet of what these cells are actually doing inside a supercentenarian's body, which tumors or senescent cells they are patrolling, or whether their presence is causally linked to longevity rather than simply correlated with it.

What Comes Next in Supercentenarian Immune Research

The authors call for in-vivo functional studies to confirm what these cells target and how they eliminate them. Larger cohorts with detailed health histories would help distinguish whether the CD4 CTL signature predicts longevity or merely accompanies it. There is also the question of whether this pathway could be boosted pharmacologically in people who are not already supercentenarians, a question that will require understanding what drives the clonal expansion in the first place.

Common Questions

Can I get a test to measure my CD4 CTLs? Not through standard clinical testing. CD4 CTLs require specialized flow cytometry or single-cell profiling to distinguish from conventional CD4 helper cells; this is currently a research tool, not a routine lab panel.

Does having more CD4 CTLs mean I am protected from cancer? The TCR overlap with cancer patient samples is intriguing, but this is correlational and exploratory. No causal link between CD4 CTL levels and cancer protection has been established in this study.

Is this related to the immune aging I've read about with CMV? Yes, partially. CMV reactivation is one of the persistent antigen sources the authors propose could be driving CD4 CTL expansion. Prior research has shown these cells can target CMV antigens on senescent cells, so the virus connection is plausible but not confirmed as the primary driver here.

Does this have implications for autoimmune disease? The authors flag the "double-edged sword" possibility: the same cells that clear damaged tissue could trigger pathological tissue damage in certain contexts. People with autoimmune conditions should not assume more CD4 CTL activity is straightforwardly beneficial.

References

1. Kosuke Hashimoto, Miki Kojima-Ishiyama, Hajime Inokuchi, et al. (2026). CD4 CTLs in supercentenarians: Signs of adaptive expansion in healthy aging. Cell Reports. https://doi.org/10.1016/j.celrep.2026.117728
2. Amal I. Khazi, Amber Ahmad (2025). Gut-Immune Interplay: Decoding the Microbiome’s Impact on Immunity and Diseases. Journal of Pharmacy and Bioallied Sciences. https://doi.org/10.4103/jpbs.jpbs_1377_25
3. Henok Ayalew Tegegne, Tor C. Savidge (2025). G ut microbiome metagenomics in clinical practice: bridging the gap between research and precision medicine. Gut Microbes. https://doi.org/10.1080/19490976.2025.2569739
4. Yanrong Wang, Beibei Huang, Xue Wei, et al. (2026). Gut microbiota metabolic reprogramming drives the development of metabolic diseases in the host. Gut Microbes. https://doi.org/10.1080/19490976.2026.2644681